Recently, Tianjin Industrial and Information Technology Bureau released the second batch of the 2023 Specialized and New Small and Medium-sized Enterprises. Laviana Pharma was included in the list for its exceptional performance in pharmaceutical research and development, as well as manufacturing services.

The Specialized and New Enterprise Projectis a crucial initiative introduced by the government to foster the high-quality growth of small and medium-sized enterprises. Its aim is to encourage these enterprises to pursue a specialized, sophisticated, distinctive, and innovative development strategy, thereby enhancing their capacity for independent innovation and core competitiveness. The specialized and new small and medium-sized enterprises hold a significant market share in domestic segments, and their main products play a crucial role in meeting unfulfilled demands and addressing weaknesses in the market. Laviana Pharma, as a specialized and new small and medium-sized enterprise, has established a strong market presence and competitive edge in the fields of pharmaceutical research and development, as well as manufacturing services.

The fact that Laviana Pharma has been included in the list is a testament to its innovative capacity, expertise, and core competitiveness in pharmaceutical research and development, as well as manufacturing services. Laviana Pharma will leverage this opportunity to advance the development of its core business by addressing weaknesses and maximizing strengths. We will also boost our innovation capability through strategic investments and by executing a specialized, sophisticated, distinctive, and innovative development strategy.

To accomplish this objective, we will enhance technological innovation, management innovation, and service innovation. This will help us boost our core competitiveness, improve communication and collaboration with both domestic and international partners, and foster collaborative innovation along the entire industrial chain. Simultaneously, we will persist in optimizing and refining our service processes, elevating service quality, and bolstering technological innovation capabilities. By offering global customers top-notch, efficient one-stop CDMO comprehensive services, we aim to expedite global pharmaceutical innovation.